Allergy immunotherapy is a treatment to prevent allergic reactions caused by food, grass pollen, dust, and bee venom among other causes. Allergy immunotherapy aids in controlling symptoms among people suffering from allergies such as rhinitis, asthma, and conjunctivitis, among other common allergies.
Allergy immunotherapy involves injections on a regular basis that generally increase the dosage to develop the resistance in the patient. With a progressive increase in dosage, the patient's immunity system becomes less fragile due to the increased production of blocking antibodies that fight the foreign substances that cause allergies.
At present, there are three main types of allergy immunotherapy products in use, namely sublingual allergy immunotherapy (SLIT), subcutaneous allergy immunotherapy (SCIT)/injection, and oral allergy immunotherapy. Among these, SLIT offers treatment without injections, instead treating the allergies with tablets.
Tablets used in the SLIT treatment are used to treat allergies caused by ragweed, grass pollen, and dust mites, and are approved by the US Food and Drugs Administration (FDA). However, SLIT offers treatment for only one type of allergen and does not prevent curbing the possibility of developing other kinds of allergies.
This gives an edge to SCIT treatment, which is considered the most effective form of allergy immunotherapy since it simultaneously prevents the development of asthma and other allergies. As people across the world grow highly sensitive to different types of allergies, the proliferating need for effective fighting methodologies will drive the market on a positive growth trajectory.
Increasing Incidence of Allergies Calls for Efficient Treatments
The rising prevalence of allergies year-on-year worldwide is propelling demand for effectual allergy immunotherapy. For instance, allergic rhinitis is among one of the most common allergies in the world, affecting roughly 10% to 30% of the global population.
According to the estimates of the American Academy of Allergy Asthma & Immunology, nearly 7.8% of the American population aged above 18 develop allergic rhinitis.
Likewise, in 2012, over 17.6 Mn adults and 6.6 Mn children were reported to be diagnosed with rhinitis. The number grew to 20 Mn adults in 2015, thus creating demand for treatments that improve the lifestyle and offer relief from the effects of the allergy.
Along similar lines, other allergies such as asthma, skin allergies, and food allergies, are also quite prevalent across the world and continue to drive demand for immunotherapy.
In 2016, the World Health Organization (WHO) estimated that over 339 people suffer from asthma globally and attributed more than 400,000 deaths to asthma in that year. By the same token, Food Allergy Research & Education (FARE) reported that over 32 Mn people in the US suffer from food allergies, necessitating emergency medical care for one person in every 3 minutes to seek.
Similarly, new research by the Journal of Allergy and Clinical Immunology (JACI) estimated that 2-37% of the European population has a self-reported food allergy. As people become increasingly aware of the availability of these treatments, an increasing number of people are willing to seek treatment, driving the allergy immunotherapy market on a remunerative path.
High Demand for Advanced Procedures
The growing incidence of allergies and the subsequent spending on medical treatments are enabling market players to enhance their treatment offerings. Players are enhancing the existing SLIT drugs, which have proven efficient in treating airway allergies, atopic dermatitis, and a few food allergies.
Recent surveys have suggested that SLIT remains a popular choice among consumers over SCIT, despite its limitations, owing to its accessibility. Moreover, it has been noted that the prevalence of food allergy rises 10% every year, leading to higher demand for immunotherapy for food allergies.
By the same token, oral immunotherapy is gaining prominence among medical professionals and patients, especially in the treatment of allergic rhinitis. Oral immunotherapy is majorly used to control the incidence of allergic reactions caused by accidental or unintentional allergen exposures for individuals with minimal levels of tolerance. On this premise, market players are focusing on improving their offerings on the oral immunotherapy front.
On the other hand, macroeconomic factors such as increasing levels of pollution, changing eating habits, and increased consumption of alcohol are resulting in increased prevalence of skin and other allergies, further boosting the need for allergy immunotherapy.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Key Challenges: High Cost and Side Effects
Allergy immunotherapy is a longer process than conventional therapies, prolonging for 3 to 5 years based on the type and severity of the allergy. It is likely to instigate patients to discontinue halfway through the treatment, owing to financial constraints during the process. This is expected to pose a challenge to the growth of the market to an extent.
On these lines, it is to be noted that allergy immunotherapy is relatively more expensive than traditional medication therapies due to the lengthy nature. The annual cost of allergy treatment is around $1000, with oral therapy costing $4000, while SLIT going beyond $7000. As a result, patients rely on healthcare insurance to cover their expenses. When not covered under insurance, those who cannot afford the treatment have no other option but to resort to temporary medication. The high cost of the treatment is limiting the adoption, thereby hindering the overall growth.
On the other hand, the side-effects of these treatments are expected to hold back the growth. Approximately 1.5% of patients undergoing oral immunotherapy experience side effects such as respiratory, gastrointestinal, or skin-related disorders, thus further restraining the healthy growth of the market.
Europe Allergy Immunotherapy Market
Europe is expected to remain the largest regional market for allergy immunotherapy during the assessment period, accounting for more than half of the global market value. The region's dominance is attributed to the presence of a wide population base with various allergies. The European Academy of Allergy and Clinical Immunology (EAACI) reports that over 150 Mn people, representing 20% of the region's population, currently suffer from chronic food allergies.
Allergic rhinitis and asthma have been identified as the most common allergies, affecting 100 Mn and 70 Mn people respectively. Furthermore, the organization reported that by 2025, 50% of Europe’s population will be affected by allergies, thus creating a lucrative growth opportunity for the allergy immunotherapy market.
By the same token, the prevalence of allergies in Europe is also mounting into a huge economic burden, due to consequential productivity losses in European nations. On the back of these factors, European governments and bodies including EAACI are working on raising awareness among people and are calling for better medical education and treatments, thereby positively influencing the growth of the market in the region.
Request a sample specific to Europe market
North America Allergy Immunotherapy Market
Although North America holds a relatively lower share than Europe, it will remain the second most lucrative region through the assessment period. The US is poised to remain at the forefront of the North American market, accounting for the majority of market value owing to the high prevalence of allergies in the region.
As per the estimates of the American College of Allergy, Asthma (ACAAI), allergies are the sixth leading cause of chronic illness in the US, affecting more than 50 million people and resulting in expenses worth more than US$ 18 Bn every year.
Moreover, children are at a higher risk of allergies. According to the 2014 National Health Interview Survey (NHIS), 8.4% of US children under age 18 suffered from allergic rhinitis, 10% from respiratory allergies, 5.4% from food allergies, and 11.6% from skin allergies.
Due to the aforementioned facets, the demand for allergy immunotherapy will prevail high for the years to come.
Request a samplespecific to North America market
East Asia Allergy Immunotherapy Market
East Asia is projected to remain a prominent region for the global allergy immunotherapy market, backed by the presence of a vast population base in China, Japan, and South Korea suffering from various kinds of allergies. Allergic rhinitis is one of the most common allergies in China and has significantly increased in the previous two decades.
Similarly, according to the Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), oral immunotherapy is gaining tremendous traction in the region owing to the convenience associated with it, especially among patients suffering from allergic rhinitis. These factors will continue to drive the market on a positive growth trajectory through the assessment period.
Request a sample specific to East Asia market
Injection Remains Most Sought-out
Based on the product type, the injection segment is poised to remain the most sought out product type, accounting for nearly 2/3rd of market share through the forecast period. This is essentially attributed to higher effectiveness and quicker response to the medication.
SCIT Holds Lion's Share
By immunotherapy type, the SCIT segment is anticipated to account for the majority of market share, accounting for 2/3rd of share in global value. The high preference for injections is majorly attributed to high effectiveness and ability to treat multiple allergies, which gives it an edge over its counterpart, SLIT immunotherapy.
Allergic Rhinitis Creates Huge Demand
On the basis of indication, allergic rhinitis is forecasted to capture more than 2/5h of global market value, being one of the most common allergies worldwide. On the other hand, allergic asthma is expected to channel more than 1/5th of market share, owing to the high prevalence among children.
Pollens and House Dust Mites Remain Most Common
Among allergens, pollens and house dust mites are expected to cumulatively account for more than 2/5th of market share, holding a share of near-equal proportions. This is ascribed to the fact that they are highly common in living areas, thus easily affecting people across the world.
Institutional Sales Hold Dominance
By distribution channel, institutional sales are expected to channel the majority of revenue, due to high reliance on government and semi-government hospitals for treatments backed by their affordability. This is also attributed to the availability of reimbursements and supportive policies in government hospitals in developed economies.
Market players are leveraging the growing prevalence of allergies and are directing their efforts towards developing treatments for food allergies, in specific. To achieve the same, they are investing in research and development activities. On these lines, Aimmune Therapeutics (Nestle Health Science) became the first organization to procure FDA approval for its drug named PALFORZIA to treat food allergies, after receiving approval in 2020.
Several organizations are focusing on developing new products - both tablets and injections to stay ahead of the curve. On this premise, in April 2020, ALK Abello announced that Health Canada has approved once-daily ITULATEK, a sublingual tablet for the treatment of tree pollen allergy.
On the other hand, growing demand is compelling market players to expand their supply capacity, which has also been observed as a key trend. On this premise, In May 2020, Stallergenes Greer announced the expansion of the supply of subcutaneous products (SCIT), to cater to the growing demand.
Some of the leading players in the market are:
- ALK Abello
- Stallergenes Greer
- Allergy Therapeutics
- Aimmune Therapeutics
- Arrayit Corporation
- Biomay AG
- HAL Allergy Group
- DBV Technologies
This list is only indicative – The full list of allergy immunotherapy market players is available on request.
Allergy Immunotherapy Market Report: Scope
Historical Data Available for
USD Million for value and units for volume
Key Regions Covered
North America, Europe, East Asia, Latin America, South Asia, Oceania, and Middle East and Africa (MEA)
Key Countries Covered
US, Canada, Brazil, Mexico, Rest of Latin America, Germany, Italy, France, Spain, U.K., Russia, Rest of Europe, China, Japan, South Korea, India, Malaysia, Thailand, Indonesia, Australia, New Zealand, South Africa, and Rest of MEA
Key Segments Covered
Product, Immunotherapy, Distribution Channel, Allergen, Indication, and Region
Key Companies Profiled
ALK Abello, Stallergenes Greer, Allergy Therapeutics, Aimmune Therapeutics, Anergis, Arrayit Corporation, Biomay AG, HAL Allergy Group, DBV Technologies, and others.
Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered by the Report
- What is the market size of the allergy immunotherapy market?
The global allergy immunotherapy market is expected to reach a valuation of US$ 2,892.2 Mn by 2030.
- Which is the largest regional market for allergy immunotherapy?
Europe is expected to maintain hegemony over the regional landscape through the course of the forecast period
- Which are the top companies in the allergy immunotherapy market?
Key players operating in the market include ALK Abello (Europe), Stallergenes Greer (Europe), Allergy Therapeutics (Europe), Aimmune Therapeutics (U.S.), Anergis (Europe), Arrayit Corporation (U.S.), Biomay AG (Europe), HAL Allergy Group (Europe), DBV Technologies (Europe), and others.
- Which distribution channel is expected to channel the majority of revenue to the allergy immunotherapy market?
The institutional sales segment is expected to channel the majority of revenue to the allergy immunotherapy market through the forecast period.
- What is the outlook on the allergy immunotherapy market?
The growth of the allergy immunotherapy market is primarily attributed to the rising prevalence of allergies worldwide.
Enquiry before Buying
- Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst.
- What research methodology is followed by FMI?
FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions.
- Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
- What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers.
- Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
- How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
Allergy Immunotherapy Market - Segmentation
- SLIT Tablets
- Sublingual Immunotherapy
- Subcutaneous Immunotherapy
- Specific Immunotherapy
- Allergic Rhinitis
- Allergic Asthma
- Food Allergy
- Atopic Dermatitis
- Grass Pollens
- Weed Pollens
- Tree Pollens
- House Dust Mites
- Animal Dander
- Bee Venom
- Institutional Sales
- Government Hospitals
- Semi-Government Hospitals
- Private Hospitals
- Retail Sales
- Retail Pharmacy
- Drug Stores
- Online Pharmacy
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa